Cite
HARVARD Citation
Jones, R. et al. (2020). A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU international. pp. 292-299. [Online].